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Antibody to oxidized low-density lipoprotein and cardiovascu- expressing immunoglobulin mRNA [4], suggesting local
lar mortality in end-stage renal disease. production of antibodies. OxLDL is detected in athero-
Background. Immune response to oxidized low-density lipo- matous lesions [5–7], and it can activate lymphocyte clonesprotein (oxLDL) may modulate the process of atherogenesis
[8]. Immunoglobulins extracted from plaques recognizeand cardiovascular disease.
oxLDL [9], and antibody against oxLDL is present inMethods. We performed a prospective, observational cohort
study in 249 patients with end-stage renal disease (ESRD) to serum [6, 10–19]. To date it has not been established
examine whether the serum titer of anti-oxLDL antibody can whether immune response to oxLDL is atherogenic or
predict cardiovascular mortality. anti-atherogenic.Results. The median anti-oxLDL antibody titer was 320
Atherosclerosis is advanced [20–23] and the cardiovas-mU/mL at baseline. During the follow-up (63  23 months),
cular mortality rate is substantially elevated among pa-72 deaths including 34 cardiovascular deaths occurred. When
the subjects were divided into two groups by the median titer, tients with end-stage renal disease (ESRD) [24, 25]. Some
the high titer group showed a lower risk for cardiovascular studies showed that ESRD patients had a higher titer
mortality (P  0.040 by Kaplan-Meier analysis and log-rank
of anti-oxLDL antibody than healthy subjects [26, 27].test). Multivariate Cox proportional hazards model indicated
Elevated anti-oxLDL antibody also was reported in pa-that the lower risk of cardiovascular death in the high titer
tients with coronary artery disease [11], severe carotidgroup remained significant (hazard ratio of 0.46, 95%CI 0.23–
0.95, P  0.037) and independent of age, presence of vascular atherosclerosis [10], and peripheral artery disease [12].
complications, presence of diabetes mellitus, and elevated Although some studies failed to confirm such elevation in
C-reactive protein. In contrast, anti-oxLDL antibody titer was anti-oxLDL antibody in patients with acute myocardialnot associated with non-cardiovascular mortality.
infarction [16], cerebral infarction [15], diabetic macro-Conclusions. These results demonstrate, to our knowledge
angiopathy [14], and familial hypercholesterolemia [17],for the first time, that serum anti-oxLDL antibody titer is an
independent predictor of cardiovascular mortality in a cohort most of these observations suggest that titer of anti-
of patients with ESRD. oxLDL antibody is elevated in those with advanced ath-
erosclerosis.
In contrast to the comparison between groups with and
Since oxidized low-density lipoprotein (oxLDL) plays without advanced atherosclerosis, a few studies focused on
a central role in the initiation and progression of athero- the variation of anti-oxLDL antibody titer within healthy
sclerosis [1], immune response to oxLDL may modulate subjects. Recently, we found an inverse association be-
atherogenesis [2] and cardiovascular mortality. In ather- tween serum anti-oxLDL antibody and circulating oxLDL
omatous plaques, there are immune competent cells in- levels in healthy human subjects [18]. We also showed
cluding macrophages, activated T [3], and B lymphocytes an independent and inverse association between anti-
oxLDL antibody titer and intima-media thickness of ca-
rotid artery in a healthy population [19]. These resultsKey words: hemodialysis, atherosclerosis, oxidized LDL, atherosclero-
sis, immune response, uremia, anti-oxLDL. indicate that a high titer of anti-oxLDL antibody may
be protective against atherosclerosis among the healthyReceived for publication April 15, 2002
subjects.and in revised form June 13, 2002
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Table 1. Characteristics of the cohort
Total Low titer High titer
Number of subjects 249 125 124
Age years 55.410.4 54.69.9 56.210.9
Duration of HD years 5.4 (0.3–21.9) 5.9 (0.3–21.9) 4.8 (0.5–20.3)
Body mass index kg/m2 21.52.7 21.22.6 21.72.8
Systolic BP mm Hg 15327 15425 15130
Diastolic BP mm Hg 8514 8415 8614
Total cholesterol mmol/L 4.371.02 4.430.96 4.261.09
Triglycerides mmol/L 1.31 (0.85–11.9) 1.30 (0.42–4.27) 1.31 (0.37–5.19)
HDL cholesterol mmol/L 1.010.29 1.050.30 0.970.27a
Non-HDL cholesterol mmol/L 3.341.00 3.390.98 3.291.02
LDL cholesterol mmol/L 2.660.85 2.740.78 2.620.88
Fasting glucose mmol/L 4.851.97 4.631.56 5.062.29
Serum creatinine lmol/L 1021174 1017188 1024160
Serum albumin g/L 37.92.9 37.52.9 38.22.9b
C-reactive protein mg/L 4.0 (1.0–53) 3.5 (1.0–43) 4.0 (1.0–53)
Hematocrit % 27.44.0 27.24.3 27.63.8
Male % 40 38 43
Smoker % 23 25 20
Presence of diabetes % 18 15 20
Presence of dyslipidemia % 76 71 82c
Presence of hypertension % 83 87 77c
Presence of vascular complications % 18 18 17
Medications for dyslipidemia % 2.0 3.2 0.8
Medications for hypertension % 60 64 57
Data are summarized as mean  SD, median (range), or percentage. The “low titer” and “high titer” groups were defined based on the median (320 mU/mL) of
serum anti-oxLDL antibody titer. Definitions of diabetes mellitus, dyslipidemia and hypertension are indicated in the text. Abbreviations are: BP, blood pressure;
HDL, high-density lipoprotein; Non-HDL, non-high-density lipoprotein; LDL, low-density lipoprotein.
a P  0.05 and bP  0.064 vs. low titer groups by ANOVA
cP  0.059–0.070 vs. low titer group by chi-square test
and have limitations in evaluating the causality between between June 1992 and June 1995, and the age at entry
was 55.4  10.4 years (mean  SD). Forty-four patientsanti-oxLDL antibody titer and atherosclerotic diseases.
To date, no prospective study is available in the literature (18%) had type 2 diabetes mellitus, and their mean dura-
tion of diabetes was 21 6 years at inclusion. The diagno-that examines whether anti-oxLDL antibody is associ-
ated with increased or decreased death from cardiovas- sis of diabetes was made according to the World Health
Organization criteria [28]. Exclusion criteria includedcular disease. In the present study, we performed a co-
hort study in 249 patients with ESRD to prospectively those with type 1 diabetes who were positive for GAD
antibody, who had a past history of ketoacidosis, or whoevaluate the possible association between anti-oxLDL
antibody and cardiovascular mortality. were dependent on insulin therapy for survival. Gesta-
tional diabetes and diabetes associated with specific syn-
dromes were carefully ruled out by their history. The
METHODS
patients received three to five hours of hemodialysis,
Study design and subjects three times a week, using bicarbonate dialysate. They
gave informed consent to participate, and this study wasThis was a prospective, observational cohort study.
The cohort consisted of 249 out of 265 ESRD patients approved by the institutional ethical committee (Inoue
Hospital Approval No. 106). Table 1 summarizes base-in the MAP ESRD study (Metabolic changes, Arterio-
sclerosis and Prognosis in ESRD) that was described re- line characteristics of the subjects.
cently [23]. Sixteen subjects were excluded because anti-
Definition of dyslipidemiaoxLDL antibody data were not available. They had been
treated by regular hemodialysis for more than three months The presence of dyslipidemia was diagnosed when a
subject had one or more of the following criteria [29];at Inoue Hospital, Suita, Japan. The subjects were recruited
from those who were dialyzed during the morning ses- (1) low-density lipoprotein cholesterol of 100 mg/dL
(2.58 mmol/L) or higher, (2) non-high-density lipopro-sions, so that blood tests were done after an overnight
fast. Patients were excluded when they had severe illness tein (non-HDL) cholesterol of 130 mg/dL (3.36 mmol/L)
or higher, (3) plasma triglycerides of 150 mg/dL (1.69or apparent acute inflammatory symptoms. The patients
corresponded to 85% of those who received hemodialy- mmol/L) or higher, (4) HDL cholesterol of 40 mg/dL
(1.03 mmol/L) or lower, and (5) use of one or more lipid-sis in morning sessions, or 50% of the total hemodialysis
patients in this hospital. The subjects were registered lowering drugs. According to the criteria, a total of 189
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subjects, including five subjects taking statins, were diag- Vienna, Austria) as previously described [18, 19]. Test
sera were prediluted with buffer, and incubated at 37Cnosed to have dyslipidemia at baseline.
for 90 minutes in 96-well microtiter plates precoated with
Definition of hypertension copper-oxidized LDL. After washing, the wells were in-
cubated with anti-human IgG antibody conjugated withBlood pressure was measured with a standard mercury
sphygmomanometer and cuffs adapted to arm circumfer- a specific peroxidase at room temperature for 30 minutes.
The wells were washed, added with tetramethylbentidineence, after the subject had rested in a supine position
for at least five minutes. The systolic and diastolic blood and incubated at room temperature for 15 minutes in
the dark. Color development was stopped by addingpressure levels were taken as the points of appearance
and disappearance of Korotkoff sounds, respectively. sulfuric acid. The absorbance at 450 nm was read by a
microplate reader. Antibody (Ab) titer was calculatedThe average of three measurements was used for analy-
sis. The presence of hypertension was diagnosed when by constructing a standard curve using the standards
included in the kit; the unit for oxLDL Ab was defineda subject had one or more of the following criteria: (1)
systolic blood pressure of 140 mm Hg or higher, (2) by the manufacturer. Intra-assay and interassay repro-
ducibility (CV) of the assay was5% and10%, respec-diastolic blood pressure of 90 mm Hg or higher, and (3)
use of one or more anti-hypertensive drugs [30]. Ac- tively [18]. The presence of oxidized LDL in the test
serum did not interfere significantly with the assay ascording to the criteria, 207 subjects were diagnosed to
have hypertension at baseline. previously described [18].
Other measurementsDefinition of elevated C-reactive protein
The median of C-reactive protein level was 4.0 mg/L, Blood was drawn in the morning after an overnight
fast of at least 12 hours before starting a dialysis session.which was also the upper limit of the normal range of
the assay. C-reactive protein levels higher than 4 mg/L Whole blood was used for hematocrit, ethylenediamine-
tetraacetic acid (EDTA)-plasma for lipids, and serumwere defined as elevated in this study, and 125 patients
had an elevated C-reactive protein concentration at for other biochemical assays. Total cholesterol was mea-
sured enzymatically using a commercially available kitbaseline.
(Wako Pure Chemicals, Osaka, Japan). HDL cholesterol
Pre-existence of vascular complications a baseline was measured after precipitating apolipoprotein B-con-
taining lipoproteins with dextran sulfate and magnesiumThe presence of vascular complications was evaluated
by clinical information regarding coronary, cerebral, and chloride. Non-HDL cholesterol was calculated by sub-
tracting HDL cholesterol from total cholesterol. Otherperipheral artery diseases and aortic aneurysm. Coro-
nary artery disease was diagnosed when a subject had measurements were performed using routine methods.
one of more of the following criteria: (1) past history of
Outcome data collectionpercutaneous coronary intervention or coronary artery
bypass grafting, (2) presence of significant stenosis by The cohort was followed up to December 1998. During
the follow-up, 47 patients moved away from Inoue Hos-coronary angiography, (3) presence of ST-T abnormali-
ties on electrocardiogram associating typical symptoms pital: the outcome data of 34 out of the 47 patients could
be obtained, while the remaining 13 patients includingattributable to angina pectoris, and (4) use of one or
more medications for coronary ischemia. Thirteen pa- one who underwent renal transplantation were censored.
At the end of the follow-up, 162 patients were confirmedtients were diagnosed to have coronary artery disease.
Cerebrovascular disease was diagnosed by past history to be alive on hemodialysis and 74 to be dead. The mean
follow-up period was 63  23 months.that had been confirmed by positive findings of infarction
or bleeding by x-ray computed tomography or magnetic Date and cause of death were obtained by reviewing
the hospital record forms. For patients transferred toresonance imaging. Seventeen patients had such past
history. Peripheral artery disease was diagnosed in four other dialysis units, we reviewed the questionnaire forms
filled by the attending physicians at the units. The 74patients with intermittent claudication and/or leg pain
at rest when significant arterial stenosis was confirmed deaths during the follow-up included 34 fatal cardiovas-
cular events: 8 deaths attributable to coronary heart dis-by angiography. Diagnosis of aortic aneurysm was made
by x-ray computed tomography in one patient. At base- ease, 5 to cerebrovascular disease, 12 to congestive heart
failure, and 9 to sudden death. Sudden death was definedline, 44 patients had one or more of the above vascular
complications. as a witnessed death that occurred within one hour after
the onset of acute symptoms, with no evidence of acci-
Measurement of anti-oxLDL antibody dent or violence. The 40 fatal non-cardiovascular causes
were: infectious disease (N  17), hepatic failure (N Anti-oxidized LDL antibody was measured by ELISA
using a commercially available kit (OLAB, Biomedica, 6), cancer (N  5), and bleeding including disseminated
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intravascular coagulation (N  4), cachexia (N  3),
respiratory failure (N  3), acute pancreatitis (N  1)
and suicide (N  1).
Statistical analysis
Data were summarized as mean  SD for continu-
ous variables. The difference between mean values was
assessed by analysis of variance (ANOVA). Data with a
skewed distribution, such as serum anti-oxLDL antibody
titer, were summarized as median (range), and the com-
parison between groups was performed using the non-
parametric Mann-Whitney U test. Correlation between
two parameters was tested by Spearman’s rank correla-
tion method. Survival curves were estimated by the Kap-
lan-Meier method followed by log-rank test. Prognostic
variables for survival were examined using univariate and
Fig. 1. Serum anti-oxidized low-density lipoprotein (anti-oxLDL) anti-
multivariate Cox proportional hazards regression models. body titer in the cohort of patients with end-stage renal disease (ESRD).
Serum anti-oxLDL antibody at baseline showed a skewed distributionCovariates that were significant in univariate analysis
with a median of 320 mU/mL (range 103 to 1558 mU/mL; N  249).were forced into the multivariate Cox model. P values
less than 0.05 were considered significant. All these anal-
yses were performed using statistical software (StatView 5,
SAS Institute Inc., Cary, NC, USA) for Windows per-
tion of hemodialysis treatment and gender tended to pre-sonal computers.
dict cardiovascular mortality at a borderline significance.
Other variables including medications for hypertension
RESULTS or dyslipidemia did not show significant relationship with
cardiovascular mortality. Also, cardiovascular mortalityDistribution of serum anti-oxLDL antibody titer
did not show a significant association with HDL choles-Serum anti-oxLDL antibody titer at baseline showed
terol, non-HDL cholesterol, LDL cholesterol, triglycer-a skewed distribution with a median of 320 mU/mL
ides, systolic blood pressure, or diastolic blood pressure(Fig. 1). This value in the hemodialysis population was
(data not shown).significantly higher than that of 446 healthy subjects with
Then, the five significant univariate predictors of car-similar age in our previous study (median 254 mU/mL,
diovascular mortality were forced into the multivariateP  0.0002 by Mann-Whitney U test) [19].
Cox regression model to identify independent predictors
Kaplan-Meier analysis of relationship between (Table 3). The results indicated that the presence of vas-
anti-oxLDL antibody and mortality cular complications, age, and titer of anti-oxLDL antibody
The subjects were divided into two groups according were independent predictors of cardiovascular mortality.
to serum anti-oxLDL antibody titer, and prognosis was Again, a higher titer of anti-oxLDL antibody was a pre-
compared by Kaplan-Meier analysis (Fig. 2). The high dictor of a lower risk of death from cardiovascular causes
titer group had a significantly lower risk of cardiovascular with a hazards ratio of 0.46 (95% confidence interval,
death than the low titer group (P  0.040). In contrast, 0.23-0.95, P  0.037).
such a trend was not found in non-cardiovascular mortal-
ity between the two groups (P  0.518). Predictors of non-cardiovascular mortality in
univariate and multivariate Cox modelsPredictors of cardiovascular mortality in univariate
Similar analyses were performed to examine the asso-and multivariate Cox models
ciation of non-cardiovascular mortality with anti-oxLDLFirst, univariate Cox proportional hazards models
antibody and other variables (Table 2). Significant uni-were used to evaluate the association of cardiovascular
variate predictors of non-cardiovascular death were age,mortality with anti-oxLDL antibody and 12 other vari-
serum albumin, C-reactive protein, and presence of dia-ables (Table 2). Significant univariate predictors of car-
betes mellitus, whereas other factors including anti-diovascular mortality were age, elevated C-reactive pro-
oxLDL antibody were not significantly associated withtein, presence of diabetes mellitus, presence of vascular
non-cardiovascular mortality. These four covariates re-complications, and the titer of anti-oxLDL antibody. A
mained significant in the multivariate Cox model (Ta-higher anti-oxLDL antibody titer was significantly asso-
ciated with a lower risk of cardiovascular death. Dura- ble 4).
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Fig. 2. Anti-oxLDL antibody at baseline and
mortality. The cohort of 249 patients with
ESRD was divided into two groups according
to serum titer of anti-oxLDL antibody titer,
and mortality rates were compared by the
Kaplan-Meier method followed by log-rank
test. Those with a higher titer showed a signifi-
cantly lower risk of cardiovascular mortality.
Table 2. Univariate association between individual covariates and mortality by the Cox proportional hazards model
Cardiovascular Non-cardiovascular
Variable HR (95% CI) P value HR (95% CI) P value
Age per 1 year 1.08 (1.04–1.12) 0.0001 1.06 (1.03–1.09) 0.0004
Hemodialysis duration
long-term vs. short-term 1.99 (0.99–3.98) 0.052 1.41 (0.74–2.66) 0.296
Body mass index per 1 point 1.07 (0.95–1.21) 0.271 1.00 (0.89–1.13) 0.944
Serum albumin per 1 g/L 0.89 (0.80–1.00) 0.064 0.80 (0.72–0.89) 0.0001
Hematocrit per 1% 1.01 (0.93–1.10) 0.807 1.05 (0.97–1.13) 0.244
C-reactive protein
elevated vs. normal 3.09 (1.44–6.61) 0.004 2.66 (1.35–5.24) 0.005
Gender
female vs. male 0.55 (0.28–1.07) 0.079 0.60 (0.32–1.11) 0.106
Diabetes mellitus
presence vs. absence 2.48 (1.18–5.20) 0.017 3.49 (1.81–6.73) 0.0002
Smoking
smoker vs. non-smoker 1.02 (0.46–2.26) 0.953 1.14 (0.56–2.34) 0.719
Dyslipidemia
presence vs. absence 1.42 (0.59–3.44) 0.433 0.71 (0.36–1.39) 0.311
Hypertension
presence vs. absence 1.76 (0.62–4.98) 0.291 0.94 (0.43–2.04) 0.880
Vascular complication
presence vs. absence 5.63 (2.87–11.04) 0.0001 1.74 (0.83–3.66) 0.145
Medication for dyslipidemia
presence vs. absence 2.91 (0.69–12.19) 0.143 Not calculateda —
Medication for hypertension
presence vs. absence 1.22 (0.60–2.49) 0.576 0.983 (0.51–1.91) 0.960
Anti-oxLDL antibody
high vs. low 0.49 (0.24–0.98) 0.045 1.20 (0.64–2.24) 0.573
Duration of hemodialysis was categorized into short-term (5.4 years) and long-term (5.4 years or longer) according to the median level. C-reactive protein level
was categorized into normal (4.0 mg/dL) and elevated (4.0 mg/dL or higher) based on the normal range. Anti-oxLDL antibody was categorized into two groups
by the median value (320 mU/mL). The Table gives hazards ratios (95% confidence intervals) with statistical significance (P values).
a None of the five patients receiving lipid-lowering drugs (statins) experienced non-cardiovascular death
Factors associated with anti-oxLDL antibody duration of hemodialysis treatment, body mass index,
serum albumin, serum C-reactive protein levels, or plasmaFactors associated with anti-oxLDL antibody titer were
lipid parameters (data not shown).explored. No significant difference was found in anti-
oxLDL antibody titer between: genders (338 vs. 299
mU/mL, P  0.095), smokers and non-smokers (322 vs.
DISCUSSION288 mU/mL, P 0.401), those with and without diabetes
The present study examined whether a serum titer ofmellitus (314 vs. 364 mU/mL, P  0.148), those with and
anti-oxLDL antibody predicts cardiovascular mortalitywithout hypertension (406 vs. 299 mU/mL, P  0.226),
in a cohort of 249 patients with ESRD. To our knowl-and those with and without vascular complications
edge, this is the first study to demonstrate that an in-(319 vs. 321 mU/mL, P  0.951). Also, anti-oxLDL anti-
body titer did not show a significant correlation with age, creased anti-oxLDL antibody titer is an independent
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Table 3. Multivariate Cox proportional hazards models of independent predictors of cardiovascular mortality
Covariate Model 1 Model 2 Model 3 Model 4
Vascular complications 4.04 (2.05–7.96) 4.09 (2.06–8.11) 3.78 (1.91–7.47) 4.01 (2.03–7.92)
presence vs. absence P  0.0001 P  0.0001 P  0.0001 P  0.0001
Age 1.08 (1.04–1.12) 1.08 (1.03–1.12) 1.07 (1.03–1.11) 1.08 (1.04–1.12)
per 1 year P  0.0002 P  0.0002 P  0.0005 P  0.0002
Anti-oxLDL antibody 0.46 (0.23–0.95) 0.49 (0.24–1.00) 0.46 (0.23–0.95) 0.45 (0.22–0.93)
high vs. low P  0.037 P  0.05 P  0.037 P  0.031
C-reactive protein 1.89 (0.97–4.71) 2.00 (0.90–4.42) 2.15 (0.98–4.74) 2.07 (0.34–4.59)
elevated vs. normal P  0.059 P  0.089 P  0.058 P  0.072
Diabetes mellitus 1.74 (0.92–4.19) 1.83 (0.84–3.97) 1.83 (0.82–4.11) 1.94 (0.90–4.15)
presence vs. absence P  0.083 P  0.128 P  0.143 P  0.089
Serum albumin — 0.96 (0.85–1.08) — —
per 1 g/L P  0.499
Duration of HD — — 0.98 (0.91–1.05) —
per 1 year P  0.522
Gender — — — 1.24 (0.62–2.47)
male vs. female P  0.539
Global model
significance P  0.0001 P  0.0001 P  0.0001 P  0.0001
The five significant univariate predictors of cardiovascular mortality were forced into the multivariate Cox proportional hazards model to identify independent
predictors. The table gives hazards ratios (HR) and 95% confidence intervals (95% CI) with statistical significance (P values).
Table 4. Multivariate Cox proportional hazards model of vascular causes, thus showing that anti-oxLDL antibody
independent predictors of non-cardiovascular mortality
is an independent predictor of cardiovascular mortality.
Covariate HR (95% CI) P value It may be confusing that a higher titer of anti-oxLDL
Serum albumin antibody predicted a lower risk of cardiovascular death,
per 1 g/L 0.85 (0.76–0.94) 0.002 because the ESRD cohort showed a higher anti-oxLDL
Diabetes mellitus
antibody titer and a substantially elevated death rate. Thepresence vs. absence 2.63 (1.35–5.12) 0.004
Age per 1 year 1.04 (1.01–1.08) 0.011 raised titer of oxLDL antibody in our ESRD cohort is in
C-reactive protein agreement with previous studies by Maggi et al [26, 27],
elevated vs. normal 2.03 (1.02–4.04) 0.044
although there are other studies that failed to show an
The four significant univariate predictors of non-cardiovascular mortality were
increase in antibody titer in smaller numbers of patientsforced into the multivariate Cox proportional hazards model to identify indepen-
dent predictors. The Table gives hazards ratios (HR) and 95% confidence inter- with renal failure [32–34]. This apparent discrepancy be-
vals (95% CI) with statistical significance (P values). P 0.0001 for global model
tween the cross-sectional and longitudinal studies cansignificance.
be explained when one considers a change in the cohort
members due to death. Namely, in a high risk population
like patients with ESRD and those with advanced ath-
predictor of a lower risk of cardiovascular mortality in erosclerosis, patients with a low titer of anti-oxLDL anti-
patients with ESRD. body are more likely to die from cardiovascular causes
There has been a controversy regarding the role of than those with a high antibody level. Therefore, survi-
anti-oxLDL antibody in atherosclerotic diseases. In many vors would show an increased median level of anti-
studies that compared antibody levels between groups oxLDL antibody that is likely to be detected by cross-
with and without advanced atherosclerosis the anti- sectional studies.
oxLDL antibody titer was elevated in subjects with ad- Although we did not address the mechanisms by which
vanced atherosclerosis [10–12], whereas other studies anti-oxLDL antibody predicted cardiovascular mortal-
failed to confirm such a difference [14–17]. In contrast, ity, we propose several possibilities. First, anti-oxLDL
still other studies that evaluated the variation of antibody antibody may have anti-atherogenic functions. In animal
titer within healthy subjects found that anti-oxLDL anti- models, immunization with oxidatively modified LDL
body titer showed an inverse association with intima- remarkably suppressed the development of atherosclero-
media thickness of carotid [19] and femoral [31] arteries sis [35, 36], whereas immunosuppression with cyclospo-
in healthy subjects. Importantly, these cross-sectional rine A promoted atherosclerosis [37]. Horrko et al re-
studies had limitations in showing the causality of the ported that uptake of oxLDL by macrophages via the
relationship between anti-oxLDL antibody and cardio- macrophage scavenger receptor was almost completely
vascular diseases. In the present prospective cohort study, inhibited by monoclonal antibodies that recognize oxi-
a higher serum anti-oxLDL antibody titer was indepen- dized phospholipid epitopes of oxLDL [38]. Therefore,
in the presence of anti-oxLDL antibody, oxLDL parti-dently associated with a lower risk of death from cardio-
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cles generated in the subendothelium may back-diffuse hort. Therefore, the results do not answer the question
of the relative importance of IgG and IgM antibodies tointo the circulation instead of being taken up by macro-
phages. In addition, anti-oxLDL antibody may enhance oxLDL.
An important issue is what makes the inter-individualthe clearance of oxLDL particles from the circulation.
We recently found an inverse correlation between serum variation of anti-oxLDL antibody titer. In our subjects,
the anti-oxLDL antibody titer was not associated withanti-oxLDL antibody titer and plasma oxLDL concen-
tration in healthy subjects [18], supporting this possibil- age, gender, duration of hemodialysis, smoking, blood
pressure, plasma lipids, presence of diabetes mellitus, ority. Antibody-bound lipoproteins were shown to be me-
tabolized by macrophages via the Fc-receptor pathway presence of vascular complications. The antibody titer
may be affected by various genetic and acquired factors[39]. Immune complex of oxLDL and anti-oxLDL anti-
body may be taken up by macrophages outside the arte- influencing antibody production including antigen levels
within arterial wall, degree of atherosclerosis, and ure-rial wall, such as by Kupffer cells in the liver. In fact,
intravenously injected 125I-labeled oxLDL was rapidly mia itself. If so, adequacy of hemodialysis is also a possi-
ble factor affecting immune response to oxLDL, al-cleared from the circulation by hepatic Kupffer cells of
mice independent of the class A scavenger receptor [40]. though we did not measure the exact dialysis dose, such
as Kt/V at baseline.Second, although anti-oxLDL antibody itself may not
be protective against atherosclerosis, it may have a close In summary, the present study has shown that serum
titer of anti-oxLDL antibody is an independent predictorassociation with other pro- or anti-atherogenic factors.
The results of our study indicate that the association of cardiovascular death in a cohort of ESRD patients.
Further prospective studies are needed to establish thebetween anti-oxLDL antibody titer and cardiovascular
mortality is independent of pre-existing vascular compli- causality between the antibody titer and outcomes. It is
also important to examine different roles of IgG and IgMcations, age, elevated C-reactive protein and presence
of diabetes mellitus. Another possibility is that oxLDL antibodies in atherosclerosis and cardiovascular diseases.
may be a causal factor for the higher risk of cardiovascu-
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